

Early-Stage Detection of Hepatocellular Carcinoma: The Oncoguard™ Liver Solution

Elle Grevstad, PhD

Pipeline Medical Development
Exact Sciences Corporation



Executive Summary

Liver cancer has the fastest growing incidence rate of any cancer in the United States and is a leading cause of cancer-related deaths worldwide.^{1,2} Up to 85% of all liver cancers are attributed to hepatocellular carcinoma (HCC), which has a five-year survival rate of approximately 20%.^{2,3} Given the burden of disease, guidelines in the U.S. currently recommend routine surveillance of individuals at risk for HCC through biannual ultrasound imaging, with or without alpha-fetoprotein (AFP) testing.^{4,5} Patient adherence to surveillance, however, is poor, and sensitivity of the recommended methods is suboptimal.^{6,7} On average, studies suggest more than 60% of patients are not diagnosed with HCC until the later stages of disease, when treatment options are limited and curative outcomes unlikely.^{8,9}

New surveillance strategies that enable the early detection of HCC are key to improving patient outcomes. With this goal in mind, Exact Sciences developed the Oncoguard™ Liver solution, consisting of a blood-based assay for HCC detection and a specially designed patient engagement program. The Oncoguard™ Liver test measures the DNA methylation markers *HOXA1*, *TSPYL5*, and *B3GALT6* and the protein biomarker AFP and incorporates patient sex to classify samples as positive or negative for HCC. Validated using samples collected in a multicenter, case-control study, the test demonstrated enhanced sensitivity for early-stage HCC detection relative to currently available tools such as AFP and GALAD and showed high performance regardless of viral disease status or patient obesity. The test is complemented by a flexible patient engagement program that empowers patients to adhere to surveillance plans with easy-to-understand educational materials and periodic testing reminders. Together, the Oncoguard™ Liver solution provides a comprehensive approach to surveillance and constitutes a breakthrough on behalf of patients with HCC.


Introduction to Liver Cancer: Epidemiology and Burden of Disease

Liver cancer is a leading cause of death worldwide and a fast-growing burden in the United States (U.S.).¹² With >40,000 cases and >30,000 deaths reported each year, rates of liver cancer in the U.S. have more than tripled since 1980 and are projected to rise more than 2% with each additional year.^{3,10,11} If such increases are sustained, liver cancer will surpass breast and colorectal cancers to become the third-leading cause of cancer deaths in the U.S. by the year 2040 (**Figure 1**).¹⁰



Rates of liver cancer are on the rise in the U.S. Long-term outcomes are poor, with an overall five-year survival rate of approximately **20%**.³

Figure 1. Projected Cancer-Related Deaths in 2040 by Cancer Type¹⁰




Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma are the two main types of primary liver cancer.² Originating in hepatocytes rather than bile duct cells, HCC is the more common neoplasm and comprises up to 85% of total cases.^{2,12} Risk factors for HCC have been well established and are known to include hepatitis B virus (HBV), cirrhosis, and genetic conditions that can increase the likelihood of cirrhosis such as hemochromatosis, alpha-1 antitrypsin deficiency, and Wilson's disease.^{4,13,14} Cirrhosis typically arises through chronic liver injury and is found to be pre-existing in more than 80% of individuals diagnosed with HCC.^{4,14} As a result, any major causes of cirrhosis should also be seen as indirect risk factors for HCC, including HBV, hepatitis C virus (HCV), alcoholic liver disease (ALD), and nonalcoholic fatty liver disease (NAFLD).^{4,15} Other factors associated with cirrhosis and HCC include diabetes, smoking, male sex, and older age.^{16,17}

While the overall incidence of HCC has been steadily rising, the distribution of underlying etiologies is both geographically heterogeneous and changing over time.^{13,18–20} HBV has long been the dominant etiology worldwide, with particularly high prevalence in regions of sub-Saharan Africa and Eastern Asia.^{13,19} In recent decades, however, these rates have shown progressive decline in populations with effective vaccine programs and/or new anti-viral therapies.^{13,19–22} In the U.S., rates of NAFLD and

HCV have been increasing in parallel due to growing obesity and opioid epidemics, respectively.^{18,19,23} According to a population-based study spanning from 2007 to 2017, NAFLD and HCV are currently the two major drivers of liver disease mortality in the U.S. (**Figure 2**).²³

Figure 2. Distribution of Liver Disease Etiologies Leading to Mortality^a



^aBased on multiple-cause mortality data from the U.S. National Center for Health Statistics.²³

ALD, alcoholic liver disease; HBV, hepatitis B virus; HCV, hepatitis C virus; NAFLD, nonalcoholic fatty liver disease.

Early Detection of HCC: Unmet Need and Ongoing Challenge

With the early stages of liver disease characterized by minimal and/or non-specific symptoms, HCC can pose a true diagnostic challenge for physicians.^{8,13} In practice, more than 60% of patients with HCC are not diagnosed by a provider until they have reached what are considered the later stages of disease.^{8,9} At this point, curative treatments such as liver transplantation and surgical resection are no longer viable options.¹³

As a result, a patient's prognosis is largely dependent on the tumor stage at presentation, as well as a patient's performance status and level of underlying liver function at that time (Figure 3).²⁴ According to data collected by the National Cancer Institute, the five-year relative survival rate of patients with liver cancer is only 2.5% for those diagnosed with distant disease, compared with 12.0% for regional disease and 34.2% for localized disease.²⁵ In the best-case scenario, survival rates climb even higher: patients who are diagnosed with early-stage disease and eligible for a liver transplant can achieve five-year survival rates over 60% and as high as 78%.^{24,26} Calls for improved early detection of HCC have been made in recent years given this difference in outcomes.²⁷

Clinical practice guidelines for U.S. physicians currently recommend routine surveillance of patients at risk for HCC based on ultrasound imaging.^{4,5} Issued by the American Association for the Study of Liver Diseases (AASLD), the most recent guidelines specify biannual ultrasound exams with or without alpha-fetoprotein (AFP) testing.^{4,5} The AASLD also specifies a target population for surveillance that includes adults with cirrhosis and select cases of HBV without cirrhosis. In both populations, positive screens should be followed by diagnostic imaging of the abdomen using multiphasic computed tomography or magnetic resonance imaging.^{4,5}

When used, these methods of surveillance can nearly double the three-year survival rate of patients with HCC.⁷ Unfortunately, studies indicate that many providers are not up-to-date with the issued guidance, and less than 30% of eligible patients receive the recommended surveillance.^{6,28} Several test-specific limitations have also been reported. Ultrasound, for example, is operator-dependent and performs poorly in obese populations and individuals with non-alcoholic steatohepatitis (NASH) or cirrhotic heterogeneous livers.^{24,27,29,30} **As many as one in five ultrasound exams are thought to be of inadequate quality for analysis.³¹**

Guidelines intend for AFP testing to accompany, not replace, ultrasound. Nevertheless, reports show that AFP is the sole surveillance tool used in as many as 46% of cases.^{32,33} The utility of this approach is controversial, with evidence suggesting AFP is not elevated in all cases of HCC and demonstrates poor sensitivity (32–49%) in patients with early-stage disease.^{27,34,35}

GALAD (Gender, Age, Lectin-bound AFP, AFP, Des-carboxy-prothrombin) is a newer model that was designed to improve upon AFP-only testing.^{36,37} The GALAD score may be difficult to interpret because of variability associated with patient characteristics and underlying risk factors, and it has not been guideline-recommended for HCC surveillance to date.^{38–40}

Routine surveillance and early detection are the keys to better patient outcomes. Patients diagnosed with early-stage HCC can achieve five-year survival rates beyond 70% when undergoing surgical resection or liver transplantation, compared with a median survival of approximately 1 year for patients with advanced HCC.^{9,26}



Figure 3. Stages of Hepatocellular Carcinoma




Figure reprinted with permission from Massachusetts Medical Society.²⁴ BCLC, Barcelona Clinic Liver Cancer; ECOG-PS, Eastern Cooperative Oncology Group Performance Status.

The Oncoguard™ Liver Solution: A New Approach to HCC Surveillance

Over the last decade, liquid biopsy has emerged as a promising new tool for the detection of multiple cancer types.^{41,42} This approach represents a minimally-invasive alternative to surgical biopsy and involves sampling and analyzing an individual's blood, urine, saliva, or other body fluid for the presence of informative biomarkers.^{41,43} In oncology, most liquid biopsies target biomarkers that are shed by a tumor and released into the bloodstream, including those from circulating tumor cells, circulating tumor DNA (ctDNA), and extracellular vesicles.⁴³ In HCC, this can also include methylated DNA markers (MDMs) — a subset of ctDNA showing aberrant methylation of gene promoter regions.^{44,45}

Researchers at Exact Sciences recently developed a high-performance assay for HCC surveillance using this technology. Known as the Oncoguard™ Liver test, the innovative new tool is a simple-yet-sophisticated blood test that predicts the likelihood of HCC using a combination of methylated DNA and protein biomarkers. The Oncoguard™ Liver test was created in collaboration with leading experts at the Mayo Clinic and built on a clinical development platform designed to ensure robust results with real-world applicability.

The development process began in the biomarker discovery phase, with the identification of >300 potential MDMs.⁴⁶ Candidate regions were selected when there was evidence of differential hypermethylation across case and control samples and underwent biological validation in independent tissue samples. MDMs were further interrogated in phase 1/2 studies using samples of blood plasma rather than frozen tissue,⁴⁶ and a subset of 10 high-performing MDMs were ultimately chosen for further evaluation.

To enable further evaluation of potential markers, a multicenter study was conducted for the purpose of large-scale data collection ([ClinicalTrials.gov, NCT03628651](https://clinicaltrials.gov/ct2/show/study/NCT03628651)).⁴⁷ The study enrolled a combined 700 cases and 1400 controls across sites in the U.S., Europe,


and Asia, and represents one of the largest case-control studies of HCC in recent history. Specimens collected as part of this effort were then used across multiple phases of product development, including marker selection, algorithm development, and clinical validation studies (**Figure 4**). In all phases, cases were defined as individuals with untreated HCC who had been clinically diagnosed within the past six months and controls as individuals with a definitive lack of HCC who were undergoing surveillance imaging procedures. Unique samples were used for each phase of development and carefully selected to be representative of the distribution of disease etiologies found in the U.S. (ie, HCV, NAFLD, ALD, HBV).

Results were consistent across all phases of development and highlight the test's ability to provide reliable results for a broad group of patients with varied etiologies of disease. During **MARKER SELECTION**, the 10 MDMs identified previously were analyzed along with three protein biomarkers. Copy numbers and protein values were entered into a logistic regression analysis and used to classify samples as either positive or negative for HCC. This initial analysis identified three MDMs (*HOXA1*, *EMX1*, *TSPYL5*), two protein biomarkers (AFP, AFP-L3), and one reference DNA marker (*B3GALT6*) as contributing variables. When combined, the newly developed panel demonstrated 71% early-stage sensitivity and 92% late-stage sensitivity at 90% specificity.⁴⁸

The panel was refined during the subsequent **ALGORITHM DEVELOPMENT** phase and a simpler model with only five predictors (*HOXA1*, *TSPYL5*, *B3GALT6*, AFP, and patient sex) was selected. Results were consistent with the initial findings, showing 72% early-stage sensitivity and 96% later-stage sensitivity at 88% specificity.⁴⁹ The optimized panel demonstrated higher sensitivity for early-stage HCC compared with either AFP (31% at a cutoff of 20 ng/mL) or GALAD (67% at a cutoff of -0.63) and similar performance across patients with both viral and non-viral disease status.⁴⁹

The five-marker panel underwent **CLINICAL VALIDATION** in the final phase of development. Blood specimens from 156 cases and 245 controls were analyzed using the model established in the algorithm development study.⁵⁰

Figure 4. The Development Journey of the Oncoguard™ Liver Test



^aThe sample sizes for the marker selection, algorithm development, and clinical validation studies do not sum to the total number of subjects enrolled in the sample collection study (NCT03628651).

Table 1. Comparative Test Performance

Biomarker Test	Sensitivity, % (95% CI)				Specificity % (95% CI) [n=245]
	Milan Criteria [n=68]	Early-Stage (BCLC 0 + A) [n=78]	Later-Stage (BCLC B + C) [n=78]	Overall [n=156]	
Oncoguard™ Liver Test	81 (70–88)	82 (72–89)	94 (86–97)	88 (82–92)	87 (82–91)
AFP (≥20 ng/mL)	41 (30–53)	40 (30–51)	77 (66–85)	58 (51–66)	100 (98–100)
GALAD (≥-0.63)	71 (60–80)	71 (60–79)	91 (83–96)	81 (74–86)	93 (90–96)

AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; GALAD, Gender, Age, Lectin-bound AFP, AFP, Des-carboxy-prothrombin.

Similar to earlier results, the panel showed 82% early-stage sensitivity and 94% later-stage sensitivity at 87% specificity (Table 1).⁵⁰ Additional analyses comparing the Oncoguard™ Liver test to currently available surveillance tools were also conducted. Results indicated that sensitivity of the Oncoguard™ Liver test (82%) was superior to both AFP (40% at a cutoff of 20 ng/mL, $p < 0.001$) and GALAD (71% at a cutoff of -0.63 , $p = 0.03$) for patients with early-stage HCC. The test also demonstrated enhanced sensitivity (81%) for patients within the Milan criteria (ie, a single tumor ≤ 5 cm in size or up to three nodules ≤ 3 cm in size without macrovascular invasion or extrahepatic spreading) relative to historic ultrasound performance ($\sim 47\%$ per a recent meta-analysis).⁵¹ Sensitivity of the Oncoguard™ Liver test was similar regardless of viral disease status or patient obesity (body mass index < 30 or ≥ 30 kg/m²) (Table 2).⁵⁰

With rigorous methodology leading to consistent results across all phases of development, physicians can be confident the Oncoguard™ Liver test will translate into real-world practice and provide substantial benefit to their patients at risk for HCC.

Performance, Access, Adherence: A Three-Pronged Approach to HCC Surveillance

A high-performance assay has little value if it cannot be implemented successfully, and real-world data suggest that access and adherence are both significant problems for today's patient.^{6,52,53} Indeed, while an estimated three million patients qualify for HCC surveillance in the U.S., a recent meta-analysis suggests surveillance utilization is currently less than 30%.⁶ Survey-based studies have reported several barriers to surveillance completion, including scheduling difficulties, transportation problems, and costs associated with testing.⁵² Adherence can also depend on a patient's understanding of disease risk and a provider's opportunity to educate the patient given limited time and competing clinical concerns (e.g., heart disease, diabetes).^{52,53}

The Oncoguard™ Liver solution is designed to address these issues. The test itself is a simple blood test and requires only a single visit to complete. The blood can be collected in a provider's practice or an associated laboratory, which offers potentially greater convenience

82%



The Oncoguard™ Liver test maintains high sensitivity (ie, approximately 82%) at the early stages of disease, when diagnosis is at its most critical. A clinical validation study shows that performance is also high across important subgroups, making the Oncoguard™ Liver test a logical choice for real-world clinical practice.

Table 2. Clinical Validation Performance in Select Subgroups

Subgroup	Sensitivity, % (95% CI)				Specificity % (95% CI)	
	Milan Criteria	Early-Stage (BCLC 0 + A)	Later-Stage (BCLC B + C)	Overall		
Viral Status^a	Viral	85 (70–93)	84 (71–92)	96 (87–99)	91 (83–95)	90 (83–94)
	Non-viral	77 (58–89)	80 (63–91)	92 (75–98)	86 (74–92)	84 (76–90)
Obesity^b	BMI < 30 kg/m²	86 (73–94)	85 (72–93)	96 (86–99)	90 (83–95)	87 (80–91)
	BMI ≥ 30 kg/m²	71 (51–85)	77 (59–88)	92 (76–98)	84 (72–91)	88 (80–93)

^aViral status unknown for 6 patients with HCC and 9 control subjects; ^bBMI data missing for 6 patients with HCC and 6 control subjects.

BCLC, Barcelona Clinic Liver Cancer; BMI, body mass index.

to patients than the imaging procedures that are today's standard of care. In an effort to help empower patients to take control of their own care, the Oncoguard™ Liver solution also includes a complementary patient engagement program. Components of the specially designed program include an informational brochure, mailed outreach materials, and periodic re-screen reminders, all written in patient-friendly language. Providers also receive periodic reports of patients who may qualify for surveillance and be due for testing. Tailored approaches like these (e.g., electronic reminders, mailed outreach) have been shown to increase adherence to surveillance by over 50% in previous studies^{6,54,55} and set the Oncoguard™ Liver solution apart from currently available tools.

Summary

Routine surveillance is the key to early detection and curative outcomes in patients with HCC. In the current landscape, however, less than 30% of patients receive the recommended surveillance for HCC and more than 60% are not diagnosed until the later stages of disease.^{6,8,9} With this in mind, Exact Sciences developed the Oncoguard™ Liver solution: a comprehensive approach to surveillance that integrates a novel blood-based assay for HCC detection with a tailored patient engagement program for patient adherence. The clinically validated test uses a combination of DNA methylation markers, AFP, and biological sex to identify patients in need of additional diagnostic follow-up and demonstrates enhanced sensitivity for the detection of early-stage disease relative to currently available tools. A unique patient engagement program complements the test's high performance and features patient-friendly educational content and periodic re-screen reminders to help increase surveillance adherence. Together, the Oncoguard™ Liver solution represents a step forward on behalf of patients with liver disease who are at elevated risk of developing HCC.

Current approaches to surveillance are both underutilized and underperforming. The Oncoguard™ Liver solution is a newly developed blood-based liquid biopsy assay that incorporates methylated DNA and protein biomarker analyses, shows enhanced early-stage sensitivity compared with the current guideline-recommended blood test, and comes with a complementary patient engagement program designed to increase surveillance adherence.



References

1. Henley SJ, Ward EM, Scott S, et al. Annual report to the nation on the status of cancer, part I: National cancer statistics. *Cancer*. 2020;126(10):2225-2249. doi:10.1002/cncr.32802
2. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2021. doi:10.3322/caac.21660
3. American Cancer Society. Cancer facts & figures. 2021. Accessed February 1, 2021. Available at: <https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2021.html>
4. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. *Hepatology*. 2018;68(2):723-750. doi:10.1002/hep.29913
5. Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. *Hepatology*. 2018;67(1):358-380. doi:10.1002/hep.29086
6. Wolf E, Rich NE, Marrero JA, Parikh ND, Singal AG. Use of Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis: A Systematic Review and Meta-Analysis. *Hepatology*. 2020. doi:10.1002/hep.31309.
7. Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. *PLoS Med*. 2014;11(4):e1001624. doi:10.1371/journal.pmed.1001624
8. Tsuchiya N, Sawada Y, Endo I, Saito K, Uemura Y, Nakatsura T. Biomarkers for the early diagnosis of hepatocellular carcinoma. *World J Gastroenterol*. 2015;21(37):10573-10583. doi:10.3748/wjg.v21.i37.10573
9. Choi DT, Kum HC, Park S, et al. Hepatocellular carcinoma screening is associated with increased survival of patients with cirrhosis. *Clin Gastroenterol Hepatol*. 2019;17(5):976-987 e974. doi:10.1016/j.cgh.2018.10.031
10. Rahib L, Wehner MR, Matrisian LM, Nead KT. Estimated projection of US cancer incidence and death to 2040. *JAMA Netw Open*. 2021;4(4):e214708. doi:10.1001/jamanetworkopen.2021.4708
11. Petrick JL, Kelly SP, Altekruse SF, McGlynn KA, Rosenberg PS. Future of hepatocellular carcinoma incidence in the United States forecast through 2030. *J Clin Oncol*. 2016;34(15):1787-1794. doi:10.1200/JCO.2015.64.7412
12. Sia D, Villanueva A, Friedman SL, Llovet JM. Liver cancer cell of origin, molecular class, and effects on patient prognosis. *Gastroenterology*. 2017;152(4):745-761. doi:10.1053/j.gastro.2016.11.048
13. Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. *Nat Rev Dis Primers*. 2016;2:16018. doi:10.1038/nrdp.2016.18
14. Desai A, Sandhu S, Lai JP, Sandhu DS. Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive review. *World J Hepatol*. 2019;11(1):1-18. doi:10.4254/wjh.v11.i1.1
15. Kim HS, El-Serag HB. The epidemiology of hepatocellular carcinoma in the USA. *Curr Gastroenterol Rep*. 2019;21(4):17. doi:10.1007/s11894-019-0681-x
16. Scaglione S, Kliethermes S, Cao G, et al. The epidemiology of cirrhosis in the United States: A population-based study. *J Clin Gastroenterol*. 2015;49(8):690-696. doi:10.1097/MCG.0000000000000208
17. Shen Y, Risch H, Lu L, et al. Risk factors for hepatocellular carcinoma (HCC) in the northeast of the United States: results of a case-control study. *Cancer Causes Control*. 2020;31(4):321-332. doi:10.1007/s10552-020-01277-1
18. Caines A, Selim R, Salgia R. The changing global epidemiology of hepatocellular carcinoma. *Clin Liver Dis*. 2020;24(4):535-547. doi:10.1016/j.cld.2020.06.001
19. Knudsen ES, Gopal P, Singal AG. The changing landscape of hepatocellular carcinoma: etiology, genetics, and therapy. *Am J Pathol*. 2014;184(3):574-583. doi:10.1016/j.ajpath.2013.10.028
20. Choo SP, Tan WL, Goh BKP, Tai WM, Zhu AX. Comparison of hepatocellular carcinoma in Eastern versus Western populations. *Cancer*. 2016;122(22):3430-3446. doi:10.1002/cncr.30237
21. Chang MH, You SL, Chen CJ, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. *J Natl Cancer Inst*. 2009;101(19):1348-1355. doi:10.1093/jnci/djp288
22. Wong GL, Chan HL, Mak CW, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. *Hepatology*. 2013;58(5):1537-1547. doi:10.1002/hep.26301

23. Paik JM, Golabi P, Biswas R, Alqahtani S, Venkatesan C, Younossi ZM. Nonalcoholic fatty liver disease and alcoholic liver disease are major drivers of liver mortality in the United States. *Hepatol Commun*. 2020;4(6):890-903. doi:10.1002/hep4.1510
24. Villanueva A. Hepatocellular carcinoma. *N Engl J Med*. 2019;380(15):1450-1462. doi:10.1056/NEJMra1713263
25. National Cancer Institute. Cancer Stat Facts: Liver and Intrahepatic Bile Duct Cancer. 2021. Accessed February 1, 2021. Available at: <https://seer.cancer.gov/statfacts/html/livibd.html>
26. Dhir M, Lyden ER, Smith LM, Are C. Comparison of outcomes of transplantation and resection in patients with early hepatocellular carcinoma: a meta-analysis. *HPB (Oxford)*. 2012;14(9):635-645. doi:10.1111/j.1477-2574.2012.00500.x
27. Kanwal F, Singal AG. Surveillance for hepatocellular carcinoma: Current best practice and future direction. *Gastroenterology*. 2019;157(1):54-64. doi:10.1053/j.gastro.2019.02.049
28. Mahfouz M, Nguyen H, Tu J, et al. Knowledge and perceptions of hepatitis B and hepatocellular carcinoma screening guidelines among trainees: A tale of three centers. *Dig Dis Sci*. 2020;65(9):2551-2561. doi:10.1007/s10620-019-05980-1
29. Esfeh JM, Hajifathalian K, Ansari-Gilani K. Sensitivity of ultrasound in detecting hepatocellular carcinoma in obese patients compared to explant pathology as the gold standard. *Clin Mol Hepatol*. 2020;26(1):54-59. doi:10.3350/cmh.2019.0039
30. Samoylova ML, Mehta N, Roberts JP, Yao FY. Predictors of ultrasound failure to detect hepatocellular carcinoma. *Liver Transpl*. 2018;24(9):1171-1177. doi:10.1002/lt.25202
31. Simmons O, Fetzer DT, Yokoo T, et al. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. *Aliment Pharmacol Ther*. 2017;45(1):169-177. doi:10.1111/apt.13841
32. Davila JA, Morgan RO, Richardson PA, Du XL, McGlynn KA, El-Serag HB. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. *Hepatology*. 2010;52(1):132-141. doi:10.1002/hep.23615
33. Nguyen MH, Engel-Nitz NM, Bancroft T, Ozbay AB, Singal A. Gaps in hepatocellular carcinoma surveillance in a nationwide cohort of insured US patients with cirrhosis. Paper presented at: APHA 2020.
34. Di Bisceglie AM, Sterling RK, Chung RT, et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. *J Hepatol*. 2005;43(3):434-441. doi:10.1016/j.jhep.2005.03.019
35. Behne T, Copur MS. Biomarkers for hepatocellular carcinoma. *Int J Hepatol*. 2012;2012:859076. doi:10.1155/2012/859076
36. Johnson PJ, Pirrie SJ, Cox TF, et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. *Cancer Epidemiol Biomarkers Prev*. 2014;23(1):144-153. doi:10.1158/1055-9965.EPI-13-0870
37. Berhane S, Toyoda H, Tada T, et al. Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients. *Clin Gastroenterol Hepatol*. 2016;14(6):875-886 e876. doi:10.1016/j.cgh.2015.12.042
38. Yang JD, Addissie BD, Mara KC, et al. GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of GALADUS score. *Cancer Epidemiol Biomarkers Prev*. 2019;28(3):531-538. doi:10.1158/1055-9965.EPI-18-0281
39. Best J, Bechmann LP, Sowa JP, et al. GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis. *Clin Gastroenterol Hepatol*. 2020;18(3):728-735 e724. doi:10.1016/j.cgh.2019.11.012
40. Liu M, Wu R, Liu X, et al. Validation of the GALAD model and establishment of GAAP model for diagnosis of hepatocellular carcinoma in Chinese patients. *J Hepatocell Carcinoma*. 2020;7:219-232. doi:10.2147/JHC.S271790
41. Dominguez-Vigil IG, Moreno-Martinez AK, Wang JY, Roehrl MHA, Barrera-Saldana HA. The dawn of the liquid biopsy in the fight against cancer. *Oncotarget*. 2018;9(2):2912-2922. doi:10.18632/oncotarget.23131
42. Cree IA, Uttley L, Buckley Woods H, et al. The evidence base for circulating tumour DNA blood-based biomarkers for the early detection of cancer: a systematic mapping review. *BMC Cancer*. 2017;17(1):697. doi:10.1186/s12885-017-3693-7
43. Campos CDM, Jackson JM, Witek MA, Soper SA. Molecular profiling of liquid biopsy samples for precision medicine. *Cancer J*. 2018;24(2):93-103. doi:10.1097/PPO.0000000000000311
44. Zhang C, Li J, Huang T, et al. Meta-analysis of DNA methylation biomarkers in hepatocellular carcinoma. *Oncotarget*. 2016;7(49):81255-81267. doi:10.18632/oncotarget.13221
45. Chen VL, Xu D, Wicha MS, Lok AS, Parikh ND. Utility of liquid biopsy analysis in detection of hepatocellular carcinoma, determination of prognosis, and disease monitoring: A systematic review. *Clin Gastroenterol Hepatol*. 2020;18(13):2879-2902 e2879. doi:10.1016/j.cgh.2020.04.019
46. Kisiel JB, Dukek BA, R VSRK, et al. Hepatocellular carcinoma detection by plasma methylated DNA: Discovery, phase I pilot, and phase II clinical validation. *Hepatology*. 2019;69(3):1180-1192. doi:10.1002/hep.30244
47. ClinicalTrials.gov. Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma. Accessed January 30, 2021. Available at: <http://clinicaltrials.gov/ct2/show/NCT03628651>
48. Chalasan NP, Ramasubramanian TS, Bhattacharya A, et al. A Novel Blood-Based Panel of Methylated DNA and Protein Markers for Detection of Early-Stage Hepatocellular Carcinoma. *Clin Gastroenterol Hepatol*. 2020;S1542-3565(1520)31224-31226. doi:10.1016/j.cgh.2020.08.065
49. Chalasan NP, Bhattacharya A, Book AJ, et al. Improved sensitivity for early-stage hepatocellular carcinoma detection with a novel blood-based panel of methylated DNA and protein markers. *J Clin Oncol*. 2020;38(15):suppl 4577-4577. doi:10.1200/JCO.2020.38.15_suppl.4577
50. Chalasan NP, Porter K, Bhattacharya A, et al. Validation of a novel multi-target blood test shows high sensitivity to detect early-stage hepatocellular carcinoma. *Clin Gastroenterol Hepatol*. 2021. doi:10.1016/j.cgh.2021.08.010
51. Tzartzeva K, Obi J, Rich NE, et al. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. *Gastroenterology*. 2018;154(6):1706-1718 e1701. doi:10.1053/j.gastro.2018.01.064
52. Farvardin S, Patel J, Khambaty M, et al. Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis. *Hepatology*. 2017;65(3):875-884. doi:10.1002/hep.28770
53. Simmons OL, Feng Y, Parikh ND, Singal AG. Primary care provider practice patterns and barriers to hepatocellular carcinoma surveillance. *Clin Gastroenterol Hepatol*. 2019;17(4):766-773. doi:10.1016/j.cgh.2018.07.029
54. Singal AG, Tiro JA, Murphy CC, et al. Mailed outreach invitations significantly improve HCC surveillance rates in patients with cirrhosis: A randomized clinical trial. *Hepatology*. 2019;69(1):121-130. doi:10.1002/hep.30129
55. Beste LA, Ioannou GN, Yang Y, Chang MF, Ross D, Dominitz JA. Improved surveillance for hepatocellular carcinoma with a primary care-oriented clinical reminder. *Clin Gastroenterol Hepatol*. 2015;13(1):172-179. doi:10.1016/j.cgh.2014.04.033